FIELD: medicine.
SUBSTANCE: present invention relates to an application of a compound by the formula (I)
wherein X1, X2, and X3 independently represent N or CH, provided that at least two from X1, X2, and X3 represent N; Y represents N or CH; R1 and R2 independently represent (i) morpholinyl by the formula (II)
wherein the arrow indicates the bond in the formula (I); and wherein R3 and R4 independently represent H, a C1-C3alkyl, optionally substituted with one or two OH, C1fluoroalkyl, a C1-C2alkoxy, a C1-C2alcoxyC1-C3alkyl or CN; or R3 and R4 together form a divalent residue of -R5R6-, selected from a C1-C3alkylene optionally substituted with 1-2 F, -CH2-O-CH2-, -CH2-NH-CH2-, or any of the structures:
wherein the arrows indicate bonds in the formula (II); or (ii) a saturated 6-membered heterocyclic ring Z, selected from thiomorpholinyl, and piperazinyl, optionally substituted with 1-3 R7, wherein R7 in each case independently represents a C1-C3alkyl optionally substituted with one or two HE, a C1-C2fluoroalkyl, a C1-C2alcoxyC1-C3alkyl, a C3-C6cycloalkyl; or the two substituents of R7 together form a divalent residue of -R8R9-, selected from a C1-C3alkylene optionally substituted with 1-4 F, -CH2-O-CH2- or -O-CH2CH2-O-; provided that at least one from R1 and R2 represents morpholinyl by the formula II, or a prodrug, solvate, or a pharmaceutically acceptable salt of said compound, for preventing or treating a neurological disorder in a subject, wherein the neurological disorder is selected from epilepsy and a neurodegenerative disease. Also proposed is a method for preventing or treating a neurological disorder in a subject, wherein the neurological disorder is selected from epilepsy and a neurodegenerative disease.
EFFECT: compound by the formula (I) is an inhibitor of protein kinase mTOR and can be applied for preventing or treating a neurological disorder.
30 cl, 29 dwg, 15 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DIFLUOROMETHYLAMINOPYRIDINES AND DIFLUOROMETHYLAMINOPYRIMIDINES | 2015 |
|
RU2712091C2 |
| PYRIDOPYRIMIDINE COMPOUND, METHOD FOR PRODUCTION, PHARMACEUTICAL COMPOSITION AND APPLICATION OF INDICATED COMPOUNDS | 2014 |
|
RU2662713C2 |
| TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGUES AND USE THEREOF AS THERAPEUTIC AGENTS AND DIAGNOSTIC SAMPLES | 2009 |
|
RU2537945C2 |
| FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | 2014 |
|
RU2679914C9 |
| 1,2,4-TRIAZOLONE DERIVATIVE | 2011 |
|
RU2566754C2 |
| AZOLE DERIVATIVES | 2012 |
|
RU2622639C2 |
| NEW β-LACTAMASE INHIBITOR AND A METHOD OF ITS PRODUCTION | 2019 |
|
RU2800050C2 |
| NOVEL BETA-LACTAMASE INHIBITOR AND METHOD FOR PRODUCTION THEREOF | 2013 |
|
RU2693898C2 |
| CONDENSED DERIVATIVES OF IMIDAZOLE AND PYRAZOLE AS MODULATORS OF ACTIVITY TNF | 2014 |
|
RU2686117C1 |
| MORPHOLINO-SUBSTITUTED DERIVATIVES OF UREA OR CARBAMATE AS MTOR INHIBITORS | 2012 |
|
RU2616619C2 |
